Pilot study comparing dominant intraprostatic lesion volume using Ga-68 prostate-specific membrane antigen

Ajay Sasidharan1, Vedang Murthy1, Aravintho Natarajan2

  • 1Departments of Radiation Oncology.

Abstract

Insights

Gallium-68 prostate-specific membrane antigen (PSMA) PET-CT shows promise for delineating dominant intraprostatic lesions (DILs). A strong inverse relationship exists between multiparametric MRI (mpMRI) volume and %SUVmax, suggesting PSMA PET-CT can provide comparable DIL volume estimations. Total lesion PSMA (TL-PSMA) may serve as a prognostic biomarker.

Area of Science:

  • Nuclear medicine imaging
  • Radiopharmaceuticals
  • Prostate cancer diagnostics

Background:

  • Multiparametric MRI (mpMRI) is the standard for delineating dominant intraprostatic lesions (DILs).
  • Gallium-68 prostate-specific membrane antigen (PSMA) PET-CT is being explored for DIL delineation due to its high sensitivity and ease of use.

Purpose of the Study:

  • To compare autogenerated DIL volumes from Ga-68 PSMA PET-CT with standard mpMRI-delineated volumes.
  • To evaluate the correlation between imaging metrics and clinical parameters.

Main Methods:

  • Twenty patients with biopsy-proven prostate adenocarcinoma were included.
  • DIL volumes were autogenerated in Ga-68 PSMA PET-CT using various %SUVmax thresholds.
  • Volumes were compared to consensus DIL volumes from mpMRI.
  • PSMA tumor volume (PSMA-TV) and total lesion PSMA (TL-PSMA) were calculated.

Main Results:

  • Median DIL volume in mpMRI was 4 cm³.
  • Median %SUVmax corresponding to mpMRI volume was 41%.
  • A strong negative correlation (r = -0.829, P < 0.001) was observed between mpMRI volume and %SUVmax.
  • A significant correlation (r = 0.609, P = 0.004) was found between TL-PSMA and prostate-specific antigen.

Conclusions:

  • A strong inverse relationship exists between mpMRI-defined DIL volume and the %SUVmax that yields similar volumes on Ga-68 PSMA PET-CT.
  • TL-PSMA may function as a quantitative biomarker for tumor burden and prognosis.